Difference between revisions of "DMT Ovariectomy and Butyrate-Enhanced CTA 3"
(create page) |
m |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
Test of role of ovarian hormones in butyrate-enhanced CTA. Continuation of [[DMP Ovariectomy and Butyrate-Enhanced CTA]]. | Test of role of ovarian hormones in butyrate-enhanced CTA. Continuation of [[DMP Ovariectomy and Butyrate-Enhanced CTA]]. | ||
| + | |||
| + | {{Infobox experiment|align=right | ||
| + | | Name = Ovariectomy and Butyrate-Enhanced CTA 3 | ||
| + | | project = HDAC Sex Difference | ||
| + | | code = DMT | ||
| + | | protocol = 1917 | ||
| + | | funding = Chair's Fund | ||
| + | | investigators = Mukherjee, Houpt | ||
| + | | species = rat | ||
| + | | date = 2022-1-18 | ||
| + | | type = CTA | ||
| + | | drugs = butyrate, lithium, estradiol | ||
| + | | artifacts = | ||
| + | | data = https://houptlab.org/bartab/expt/?id=DMT | ||
| + | }} | ||
Dose of NaB based on [https://houptlab.org/papers/pdfs/Houpt065.pdf Kwon and Houpt, Brain Research, 1333 (2010) 36–47], PMID: 20346924 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871962/ PMCID: PMC2871962] | Dose of NaB based on [https://houptlab.org/papers/pdfs/Houpt065.pdf Kwon and Houpt, Brain Research, 1333 (2010) 36–47], PMID: 20346924 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871962/ PMCID: PMC2871962] | ||
| Line 20: | Line 35: | ||
==Agenda== | ==Agenda== | ||
| − | '''Rats arrive''' | + | '''Rats arrive''' |
| − | Female Sprague Dawley rats n=8 (dob | + | Female Sprague Dawley rats n=8 (DMT1-5: dob 2021-9-21; rcvd 2021-12-7. DMT6-8: dob 2021-10-25;rcvd 2022-1-11 |
| − | |||
<br> | <br> | ||
| Line 29: | Line 43: | ||
all rats: ovariectomized + 3mg pellet of 17-beta-estradiol (Innovative Research, Sarasota, FL) | all rats: ovariectomized + 3mg pellet of 17-beta-estradiol (Innovative Research, Sarasota, FL) | ||
| − | * DMT 1-4 : Surgery on | + | * DMT 1-4 : Surgery on 2022-1-18 |
| − | * DMT 5-8 : Surgery on | + | * DMT 5-8 : Surgery on 2022-1-19 |
| Line 72: | Line 86: | ||
[[Category:Taste Aversion]] | [[Category:Taste Aversion]] | ||
| − | [[Category: CTA Experiments]] | + | [[Category:CTA Experiments]] |
| + | [[Category:Epigenetics]] | ||
Latest revision as of 10:26, 30 November 2022
Test of role of ovarian hormones in butyrate-enhanced CTA. Continuation of DMP Ovariectomy and Butyrate-Enhanced CTA.
| Ovariectomy and Butyrate-Enhanced CTA 3 | |
|---|---|
| HDAC Sex Difference | |
| Expt Code | DMT |
| Start Date | 2022-1-18 |
| Investigators | Mukherjee, Houpt |
| Funding | Chair's Fund |
| Protocol | 1917 |
| Expt Type | CTA |
| Species | rat |
| Drugs | butyrate, lithium, estradiol |
| Data Link | https://houptlab.org/bartab/expt/?id=DMT |
Dose of NaB based on Kwon and Houpt, Brain Research, 1333 (2010) 36–47, PMID: 20346924 PMCID: PMC2871962
- 0.3 M Na Butyrate = 3.3g/100ml water
- 0.3 M NaCl = 18g/liter water (osmotic control)
Data
People
Durba Mukherjee
Agenda
Rats arrive Female Sprague Dawley rats n=8 (DMT1-5: dob 2021-9-21; rcvd 2021-12-7. DMT6-8: dob 2021-10-25;rcvd 2022-1-11
Surgery
all rats: ovariectomized + 3mg pellet of 17-beta-estradiol (Innovative Research, Sarasota, FL)
- DMT 1-4 : Surgery on 2022-1-18
- DMT 5-8 : Surgery on 2022-1-19
Carpofen 0.5 mg/kg pre-op, isoflurane and bupivicaine intra-op, carpofen 0.5 mg/kg post-op (next day). Staples removed 7 days post-op.
Day 0: Water removed 2022-1-27
Days 1-8: Water Restriction 2022-1-28 thru 2022-2-4
Weigh rats daily. Water for 10 min, ad lib food.
10 min water at 1400 daily.
Day 9: Conditioning Day 2022-2-8
- 0-30 min: saccharin 0.125%
- at 30 min: 3 ml/kg of 0.15M LiCl ip (all rats)
- at 40 min: 12 ml/kg of 0.3M NaButyrate or NaCl
ad lib water returned after final injection overnight.
Groups:
- OVX + E + LiCl + NaCl: DMT 2,3,4,6
- OVX + E + LiCl + Butyrate: DMT 1,5,7,8
Days 10 - 19: Preference Tests: 2022-2-7 to 2022-2-16
Rats CTA acquisition and extinction was measured with 24-h, 2-bottle preference tests (for ???? days). Rats were given 24-h free access to both 0.125% saccharin and water bottles, alternating position for 10 days.